LLerena A - Search Results

1

Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative.

LLerena A, Peñas-LLedó E, de Andrés F, Mata-Martín C, Sánchez CL, Pijierro A, Cobaleda J. LLerena A, et al. Drug Metab Pers Ther. 2020 Sep 1;35(3). doi: 10.1515/dmpt-2020-0143. Drug Metab Pers Ther. 2020. PMID: 32975200 No abstract available.

2

Schizophrenia and tobacco smoking in a Spanish psychiatric hospital.

LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz FJ, de Leon J. LLerena A, et al. Schizophr Res. 2003 Apr 1;60(2-3):313-7. doi: 10.1016/s0920-9964(02)00508-x. Schizophr Res. 2003. PMID: 12591592

3

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. LLerena A, et al. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.

4

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.

Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A. Dorado P, et al. Among authors: llerena a. Clin Chem Lab Med. 2005;43(3):275-9. doi: 10.1515/CCLM.2005.046. Clin Chem Lab Med. 2005. PMID: 15843230

5

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Dorado P, et al. Among authors: llerena a. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):9-19. doi: 10.1517/17425255.3.1.9. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269891 Review.

6

Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.

Peñas-Lledó EM, Dorado P, Cáceres MC, de la Rubia A, Llerena A. Peñas-Lledó EM, et al. Among authors: llerena a. Clin Chem Lab Med. 2007;45(7):835-8. doi: 10.1515/CCLM.2007.181. Clin Chem Lab Med. 2007. PMID: 17617023

7

Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.

Cáceres MC, Peñas-Lledó EM, de la Rubia A, Llerena A. Cáceres MC, et al. Among authors: llerena a. Eur J Clin Pharmacol. 2008 Jan;64(1):73-6. doi: 10.1007/s00228-007-0386-1. Epub 2007 Oct 19. Eur J Clin Pharmacol. 2008. PMID: 17952424

8

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.

Dorado P, Peñas-Lledó EM, Llerena A. Dorado P, et al. Among authors: llerena a. Pharmacogenomics. 2007 Nov;8(11):1597-608. doi: 10.2217/14622416.8.11.1597. Pharmacogenomics. 2007. PMID: 18034624 Review.

9

Subtyping undergraduate women along dietary restraint and negative affect.

Peñas-Lledó EM, Loeb KL, Puerto R, Hildebrandt TB, Llerena A. Peñas-Lledó EM, et al. Among authors: llerena a. Appetite. 2008 Nov;51(3):727-30. doi: 10.1016/j.appet.2008.04.014. Epub 2008 Apr 22. Appetite. 2008. PMID: 18501473

10

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.

Llerena A, Dorado P, Peñas-Lledó EM. Llerena A, et al. Pharmacogenomics. 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. Pharmacogenomics. 2009. PMID: 19102711 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters